Manchester Score for Prognosis in Small Cell Lung Cancer
Predicts 2 year survival of small cell lung cancer.
Result:
What pearls, pitfalls and/or tips do you have for users of the Manchester Score for Lung Cancer? Do you know of cases when it has been applied, interpreted, or used inappropriately?
It’s easy to use and the therapeutic options are pretty much the same as today. Only bicarbonate might not be used routinely, but it’s easy and cheap. This might change in the near future with the advent of new treatment options, but I have not heard as to any pitfalls with the Manchester Score.
What recommendations do you have for doctors once they have applied the Manchester Score for Lung Cancer? Are there any adjustments or updates you would make to the score based on new data or practice changes?
Not to my knowledge.
Why did you develop the Manchester Score for Lung Cancer? Was there a particular clinical experience or patient encounter that inspired you to create this tool for clinicians?
35 years ago, more prognostic information was asked by patients and treating physicians for, i.e., shared decision making, and since there is a small chance of cure in SCLC, any prognostically validated information could help to make the best treatment choice in individual cases.
How do you use the Manchester Score for Lung Cancer in your own clinical practice? Can you give an example of a scenario in which you use it?
N/A - I am retired since a few years and no more treating patients.
Thomas Cerny, MD, is the former chief of hematology and oncology at Kantonsspital St Gallen and also a professor of medical oncology at the University of Berne. He is president of the Swiss Cancer Foundation and Oncosuisse. Dr. Cerny researches multiple types of cancer including sarcoma and lung cancer.